

SOMETHING BETTER THAN HOPE

GWG Recommendations

Gil Sambrano, Ph.D.

Vice President, Portfolio Development and
Review
California Institute for Regenerative Medicine

July 24, 2020

CIRM
CALIFORNIA / STEM CELL AGENCY

COVID-19 Program

- Given the urgent need to develop treatments for COVID-19, CIRM launched a solicitation in support of promising discovery, translational, preclinical and clinical trial stage projects that could quickly advance treatments to patients in need.
- CIRM is utilizing its established partnering opportunities in Discovery (DISC1, DISC2), Translational (TRAN1), and Clinical (CLIN1, CLIN2) stages to facilitate the application, review and funding process.
- The CIRM Governing Board approved a total allocation of \$5 million to support this new program.

COVID-19 Program

Support under the DISC2, TRAN1, CLIN1, and CLIN2 program announcements is provided with the following award limitations:

Project Stage	Specific Program	Award Amount*	Award Duration
Clinical trial	CLIN2	\$750,000	24 months
Late stage preclinical	CLIN1	\$400,000	12 months
Translational	TRAN1	\$350,000	12 months
Discovery	DISC2	\$250,000	12 months
Early Discovery	DISC1	\$150,000	12 months

*Award limits are for Total Funds Requested (i.e., limit includes direct facilities costs and indirect costs)

COVID-19 Program

All projects must propose to achieve a clear deliverable within six months of project initiation to demonstrate progress toward the goal.

Program	Ready to Start	Six-Month Goal
CLIN2	IND filed/approval to treat patients	Initiate enrollment and data collection
CLIN1	Pre-IND with FDA completed	File IND with FDA
TRAN1	Therapeutic candidate w/ disease-modifying activity	Conduct pre-IND or equivalent interaction w/ FDA
DISC2	Proposal to identify a candidate for development	Have data for a viable candidate that could progress quickly to the clinic
DISC1	Great new idea	Data to confirm or reject hypothesis

Addressing Needs of the Underserved

- COVID-19 has a disproportionate impact on minority and underserved communities in California and the nation.
- CIRM clinical trial (CLIN2) projects are already required to include a plan for outreach and inclusion of minority and underserved populations in their studies.
- CIRM is asking all other applicants how their overall study plan and design has considered the disproportional impact of COVID-19 on underserved populations and the limitations, advantages and/or challenges of the proposed study in developing a product or tool that will broadly serve all populations.

GWG Recommendations

	Number of Apps	Total Applicant Request	Funds Available
Recommended for funding Score 85-100	2	\$499,974	\$272,357*
Not recommended for funding Score 1-84	8		

For each award, the final award amount shall not exceed the amount approved by the ICOC Application Review Subcommittee and may be reduced contingent on CIRM's assessment of allowable costs and activities.

*Funds available represent the amount remaining from the original \$5M allocation made to the COVID-19 program. An allocation of \$2M from recovered funds was recently approved by the Board for the DISC2 program and could also be used to fund a COVID-19 DISC2 project.

Recommended Applications

Application	Score (Median/Mean)	Votes (Y/N)	Project Type	Therapeutic Product	Applicant Request
DISC2COVID19-12007	86/85	14/1	Discovery	Biologic	\$249,974
DISC2COVID19-12020	86/86	9/5	Discovery	Cell therapy	\$250,000